NYSE •
Healthcare •
Biotechnology •
Quote as of 08/21/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization33.4 mln
Float21.08 mln
Earnings Date08/15/2026
Piotroski F-Score
4
/ 9
Borderline
Relative Strength
9
/ 100
Severely lagging
Debt / Equity
0.00
Debt-free
ROE
-92.46
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
NanoViricides Inc. is a clinical-stage biopharmaceutical company based in Shelton, Connecticut, focused on developing treatments for a wide range of viral infections. Its leading drug candidate, NV-387, is being explored in multiple forms ? including oral syrups, gummies, injections, and inhaled solutions ? to treat respiratory illnesses such as RSV, influenza, and COVID-19, with several formulations currently in human clinical trials. The company is also working on treatments for conditions like shingles, cold sores, genital ulcers, HIV, Dengue, and Ebola. Founded in 2005, NanoViricides builds its pipeline on a proprietary nanoparticle platform designed to target and neutralize viruses in the body.
